FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 326:793-798 March 19, 1992 Number 12 Next

	Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Abstract

BACKGROUND. After primary treatment for cryptococcal meningitis, patients with the acquired immunodeficiency syndrome (AIDS) require some form of continued suppressive therapy to prevent relapse. METHODS. We conducted a multicenter, randomized trial that compared fluconazole (200 mg per day given orally) with amphotericin B (1 mg per kilogram of body weight per week given intravenously) in patients with AIDS who had completed primary therapy for cryptococcal meningitis with amphotericin B (greater than or equal to 15 mg per kilogram). To be eligible, patients had to have at least two negative cultures of cerebrospinal fluid immediately before randomization. The primary end point was relapse of cryptococcal disease as confirmed by biopsy or culture. RESULTS. Of 218 patients initially enrolled, 119 were assigned to fluconazole and 99 to amphotericin B. Twenty-three patients were found not to have met the entry criteria; six other patients assigned to amphotericin B did not receive it and were lost to follow-up. Of the remaining 189 patients, after a median follow-up of 286 days 14 of 78 receiving amphotericin B (18 percent) and 2 of 111 assigned to fluconazole (2 percent) had relapses of symptomatic cryptococcal disease (P less than 0.001 by Fisher's exact test). There was a difference of 19 percent in the estimated probability of remaining relapse-free at one year between the fluconazole group (97 percent) and the amphotericin B group (78 percent) (95 percent confidence interval, 7 percent to 31 percent; P less than 0.001). Serious drug-related toxicity was more frequent in the amphotericin B group (P = 0.02), as were bacterial infections (P = 0.004) and bacteremia (P = 0.002). CONCLUSIONS. Fluconazole taken by mouth is superior to weekly intravenous therapy with amphotericin B to prevent relapse in patients with AIDS-associated cryptococcal meningitis after primary treatment with amphotericin B.

Source Information

Division of Infectious Diseases, Washington University School of Medicine, St. Louis, MO 63110.

This article has been cited by other articles:

• Karam, G. H. (2009). Infections in AIDS Patients and Other Immunocompromised Hosts. ACCP Crit Care Med Brd Rev 20: 13-40 [Full Text]  
• Duffalo, M. L. (2006). Fungal Opportunistic Infections in HIV Disease. Journal of Pharmacy Practice 19: 17-30 [Abstract]  
• Johnson, M. D., MacDougall, C., Ostrosky-Zeichner, L., Perfect, J. R., Rex, J. H. (2004). Combination Antifungal Therapy. Antimicrob. Agents Chemother. 48: 693-715 [Full Text]  
• Masur, P. b. H., Kaplan, J. E., Holmes, K. K. (2002). Guidelines for Preventing Opportunistic Infections among HIV-Infected Persons--2002: Recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America. ANN INTERN MED 137: 435-478 [Abstract] [Full Text]  
• Purdy, B. D. (2000). Management and Prevention of Opportunistic Infections in the HIV-Infected Patient. Journal of Pharmacy Practice 13: 475-498 [Abstract]  
• Aller, A. I., Martin-Mazuelos, E., Lozano, F., Gomez-Mateos, J., Steele-Moore, L., Holloway, W. J., Gutiérrez, M. J., Recio, F. J., Espinel-Ingroff, A. (2000). Correlation of Fluconazole MICs with Clinical Outcome in Cryptococcal Infection. Antimicrob. Agents Chemother. 44: 1544-1548 [Abstract] [Full Text]  
• Kovacs, J. A., Masur, H. (2000). Prophylaxis against Opportunistic Infections in Patients with Human Immunodeficiency Virus Infection. NEJM 342: 1416-1429 [Full Text]  
• Cabre, P, Smadja, D, Cabié, A, Newton, C R J C (2000). NEUROLOGICAL ASPECTS OF TROPICAL DISEASE: HTLV-1 and HIV infections of the central nervous system in tropical areas. J. Neurol. Neurosurg. Psychiatry 68: 550-557 [Full Text]  
• Shih, C.-C., Chen, Y.-C., Chang, S.-C., Luh, K.-T., Hsieh, W.-C. (2000). Cryptococcal meningitis in non-HIV-infected patients. QJM 93: 245-251 [Abstract] [Full Text]  
• Sheehan, D. J., Hitchcock, C. A., Sibley, C. M. (1999). Current and Emerging Azole Antifungal Agents. Clin. Microbiol. Rev. 12: 40-79 [Abstract] [Full Text]  
• Pfaller, M. A., Zhang, J., Messer, S. A., Brandt, M. E., Hajjeh, R. A., Jessup, C. J., Tumberland, M., Mbidde, E. K., Ghannoum, M. A. (1999). In Vitro Activities of Voriconazole, Fluconazole, and Itraconazole against 566 Clinical Isolates of Cryptococcus neoformans from the United States and Africa. Antimicrob. Agents Chemother. 43: 169-171 [Abstract] [Full Text]  
• Schell, W. A., De Almeida, G. M. D., Dodge, R. K., Okonogi, K., Perfect, J. R. (1998). In Vitro and In Vivo Efficacy of the Triazole TAK-187 against Cryptococcus neoformans. Antimicrob. Agents Chemother. 42: 2630-2632 [Abstract] [Full Text]  
• Scharfstein, J. A., Paltiel, A. D., Freedberg, K. A. (1997). The Cost-Effectiveness of Fluconazole Prophylaxis against Primary Systemic Fungal Infections in AIDS Patients. Med Decis Making 17: 373-381 [Abstract]  
• Manfredi, R., Mastroianni, A., Coronado, O. V., Chiodo, F. (1997). Fluconazole as Prophylaxis Against Fungal Infection in Patients With Advanced HIV Infection. Arch Intern Med 157: 64-69 [Abstract]  
• Murakawa, G. J., Kerschmann, R., Berger, T. (1996). Cutaneous Cryptococcus Infection and AIDS: Report of 12 Cases and Review of the Literature. Arch Dermatol 132: 545-548 [Abstract]  
• Powderly, W. G., Finkelstein, D. M., Feinberg, J., Frame, P., He, W., van der Horst, C., Koletar, S. L., Eyster, M. E., Carey, J., Waskin, H., Hooton, T. M., Hyslop, N., Spector, S. A., Bozzette, S. A., The NIAID AIDS Clinical Trials Group, (1995). A Randomized Trial Comparing Fluconazole with Clotrimazole Troches for the Prevention of Fungal Infections in Patients with Advanced Human Immunodeficiency Virus Infection. NEJM 332: 700-705 [Abstract] [Full Text]  
• Fishman, J.A., Mattia, A.R. (1995). Case 3-1995- A 29-year-old man with AIDS and multiple splenic abscesses. NEJM 332: 249-257 [Full Text]  
• Moore, R. D., Stanton, D., Gopalan, R., Chaisson, R. E. (1994). Racial Differences in the Use of Drug Therapy for HIV Disease in an Urban Community. NEJM 330: 763-768 [Abstract] [Full Text]  
• Sax, P. E., Mattia, A. R. (1994). Case 7-1994- A 55-Year-Old Heart-Transplant Recipient with a Tender, Enlarged Prostate Gland. NEJM 330: 490-496 [Full Text]  
• Como, J. A., Dismukes, W. E. (1994). Oral Azole Drugs as Systemic Antifungal Therapy. NEJM 330: 263-272 [Full Text]  
• Girard, P.-M., Landman, R., Gaudebout, C., Olivares, R., Saimot, A. G., Jelazko, P., Gaudebout, C., Certain, A., Boue, F., Bouvet, E., Lecompte, T., Jean-Coulaud, P., The PRIO Study Group, (1993). Dapsone-Pyrimethamine Compared with Aerosolized Pentamidine as Primary Prophylaxis against Pneumocystis carinii Pneumonia and Toxoplasmosis in HIV Infection. NEJM 328: 1514-1520 [Abstract] [Full Text]  
• Jewett, J. F., Hecht, F. M. (1993). Preventive Health Care for Adults With HIV Infection. JAMA 269: 1144-1153 [Abstract]